Key result
Trastuzumab combined with liposomal anthracyclines is being investigated as a potentially safer alternative to conventional anthracyclines for breast cancer treatment due to cardiac safety concerns.
Population
Patients with breast cancer
Design
Review
Authors
Loading...
Does not yet support replacing conventional anthracyclines with liposomal forms alongside trastuzumab; leaves open improved cardiac safety in breast cancer.
Liposomal anthracyclines may offer a more favorable cardiac safety profile when combined with trastuzumab for breast cancer treatment compared to conventional anthracyclines.
Antonio C. Wolff (2003) conducted a review in Breast cancer. Liposomal anthracyclines and trastuzumab was evaluated. Trastuzumab combined with liposomal anthracyclines is being investigated as a potentially safer alternative to conventional anthracyclines for breast cancer treatment due to cardiac safety concerns.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: